

# IPO Flash

November 01, 2022

---

## Index

### Global Health Ltd

- About the IPO •
- About the company •
- Industry overview •
- Key strengths of the company •
- Valuation and view •
- Financials •

Visit us at [www.sharekhan.com](http://www.sharekhan.com)

# Sharekhan

by BNP PARIBAS

For Private Circulation only

IPO Details:	
Issue opens	November 03, 2022 (Thursday)
Issue closes	November 07, 2022 (Monday)
Issue size	Rs. 2,119-2,206 crore
Type of issue	Fresh issue of equity shares aggregating 1.49-1.57 crore shares based on lower and upper end of the price band and Offer for Sale (OFS) of 5.08 crore shares
Offer size	Fresh issue of Rs. 500 crore; OFS of Rs. 1,169-1,706 crore
Face value	Rs. 2 per share
Price band	Rs. 319-336
Bid lot	44 shares
QIB portion	Not more than 50%
Non-Institution portion	Not less than 15%
Retail portion	Not less than 35%

Source: Company RHP

Note - \*The company and the selling shareholders in consultation with BRLM might offer 60% of QIB portion to anchor investors on a discretionary basis.

Global Health Ltd (GHL) is coming out with an initial public offer (IPO), consisting of a fresh issue of equity shares amounting to Rs. 500 crore and an OFS of Rs. 1,169-1,706 crores. The total issue size is Rs. 2,119-2,206 crore. The price band for the said issue is Rs. 319-336 per share. At the lower and upper price band, the fresh equity issuance stands at 1.49-1.57 crore shares. The OFS consists of 5.08 crore shares.

#### Offer for sale details

Investor Selling Shareholder	No. of Shares
Anant Investments	5,06,61,000
Sunil Sachdeva (jointly held with Suman Sachdeva)	1,00,000
<b>Total OFS</b>	<b>5,07,61,000</b>

Source: Company RHP

#### Shareholding pattern

Shareholder	Pre-issue		Post-issue*		Post-issue^	
	No of shares	Holding (%)	No of shares	Holding (%)	No of shares	Holding (%)
Promoters	8,87,25,240	35.0	8,87,25,240	33.0	8,87,25,240	33.1
Public	16,45,78,690	65.0	18,02,52,671	67.0	17,94,59,642	66.9
<b>Total</b>	<b>25,33,03,930</b>	<b>100.0</b>	<b>26,89,77,911</b>	<b>100.0</b>	<b>26,81,84,882</b>	<b>100.0</b>

Source: Company RHP (\*Lower price band; ^Upper price band)

#### Objects of the issue

Objects	Rs. crore
Repayment/prepayment of borrowings, in full or part, of Subsidiaries, GHPPL and MHPL	375.0
General corporate purposes#	125.0
<b>Fresh issue size</b>	<b>500.0</b>

Source: Company RHP

#### BLRMs

- Kotak Mahindra Capital Company Limited
- Credit Suisse Securities (India) Private Limited
- Jefferies India Private Limited
- JM Financial Consultants Private Limited

## About the company

GHL is one of the largest private multi-speciality tertiary care providers operating in North and East India, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology. Under the 'Medanta' brand, the company has a network of 5 hospitals currently in operation (Gurugram, Indore, Ranchi, Lucknow, and Patna), and 1 hospital (Noida), which is under construction. As on June 30, 2022, the company provides healthcare services in over 30 medical specialties and engages over 1,300 doctors led by highly experienced department heads and spanning an area of 4.7 million sq. ft. (msf). The company's operational hospitals have 2,467 installed beds.

The company was founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon. Dr. Trehan is the driving force behind the hospitals. The company strives to deliver world-class healthcare by establishing institutes of excellence that integrate medical care, teaching, and research all while providing affordable medical services to patients. The company's hospital at Gurugram was ranked as the best private hospital in India for three consecutive years in 2020-2022 and was the only Indian private hospital to be featured in the list of Top-200 global hospitals in 2021 and was featured in the list of Top-250 global hospitals in 2022 by Newsweek.

As at March 31, 2020, Medanta had 2,141 installed beds, which grew to 2,467 installed beds as at June 30, 2022, representing a growth of 15.23%. Upon operation of its Noida hospital, Medanta expects the number of total installed beds to exceed 3,500 at FY25-end, which will cater to domestic and international patients as part of GHL's strategy to capitalize on medical tourism.

### Key financial and operational information

Particulars	FY2020	FY2021	FY2022	Q1FY2022	Q1FY2023
Facility build-up area (million sq. ft.)	3.7	3.7	4.7	4.7	4.7
Bed capacity/installed beds	2,141	2,176	2,404	2,176	2,467
Operational beds	1,517	1,579	1,779	1,692	1,866
Total occupied bed	832	814	1,076	1,059	1,111
Average occupancy levels (%)	54.9	51.6	60.5	62.6	59.6
Number of operating theatres	65.0	65.0	69.0	65.0	69.0
Number of ICU beds	489	494	504	478	523
Income from healthcare services (Rs. crore)	1,489.6	1,417.8	2,100.4	473.2	596.1
Average revenue per occupied bed (ARPOB) (Rs.)	50,166	47,731	54,547	49,124	58,961
Average length of stays in hospitals (ALOS) (days)	3.5	3.9	3.8	4.7	3.2
OPD volumes	13,05,559	11,01,780	19,71,260	4,20,034	5,59,125
IPD volumes	83,901	76,450	1,02,359	20,732	31,351
Revenue from outpatient pharmacy business (Rs. crore)	-	11.5	53.6	9.9	18.6

Source: Company RHP; Sharekhan Research

## Income from Healthcare Services Breakdown

Particulars	FY2020		FY2021		FY2022	
	Amount (Rs. crore)	% to total	Amount (Rs. crore)	% to total	Amount (Rs. crore)	% to total
<b>Income from Healthcare Services Breakdown by Out-patient vs In-patient Type</b>						
Out - Patient Department	286.5	19.4%	231.3	16.3%	359.8	17.1%
In - Patient Department	1,194.1	80.7%	1,186.6	83.7%	1,740.6	82.9%
<b>Total</b>	<b>1,480.6</b>	<b>100.0%</b>	<b>1,417.8</b>	<b>100.0%</b>	<b>2,100.4</b>	<b>100.0%</b>
<b>Income from Healthcare Services Breakdown by Speciality type</b>						
Heart Institute	388.2	26.2%	292.8	20.7%	439.6	20.9%
Institute of Neurosciences	154.1	10.4%	148.7	10.5%	234.4	11.2%
Institute of Musculoskeletal Disorders and Orthopaedics	93.3	6.3%	52.2	3.7%	94.1	4.5%
Kidney & Urology Institute	122.0	8.2%	112.7	8.0%	151.7	7.2%
Cancer Institute	171.8	11.6%	173.8	12.3%	227.3	10.8%
Institute of Digestive and Hepatobiliary Sciences	175.3	11.8%	166.0	11.7%	214.0	10.2%
Institute of Liver Transplantation and Regenerative Medicine	64.4	4.4%	56.4	4.0%	74.8	3.6%
Medanta's Internal Medicine Division	82.8	5.6%	154.7	10.9%	236.5	11.3%
Others	228.8	15.5%	260.5	18.4%	427.9	20.4%
<b>Total</b>	<b>1,480.6</b>	<b>100.0%</b>	<b>1,417.9</b>	<b>100.0%</b>	<b>2,100.2</b>	<b>100.0%</b>

Source: Company RHP; Sharekhan Research

## Key financial and operational information for the mature and developing hospitals

Particulars	FY2020	FY2021	FY2022	Q1FY2021	Q1FY2022
<b>Mature Hospitals (in operation for more than six years from commencement of operations, as of June 30, 2022) include the hospitals at Gurugram, Indore and Ranchi</b>					
Contribution to total income (%)	98.2%	85.0%	81.6%	84.2%	76.7%
EBITDA Margin (%)	17.0%	15.7%	22.8%	21.9%	22.6%
Operational Beds	1,377	1,284	1,431	1,412	1,430
ARPOB (Rs.)	50,302.8	47,682.7	54,273.0	49,376.3	59,291.1
<b>Developing hospitals (in operation for less than 6 years from commencement of operations, as of June 30, 2022) include the hospitals at Lucknow and Patna</b>					
Contribution to total income (%)	1.9%	15.0%	18.5%	15.8%	23.4%
EBITDA Margin (%)	-81.3%	15.4%	19.6%	19.2%	22.6%
Operational Beds	280	295	298	280	335
ARPOB (Rs.)	48,062.6	48,062.6	55,883.0	47,897.0	56,499.7

Source: Company RHP; Sharekhan Research

## Brief profile of directors &amp; top management


- ♦ **Dr. Naresh Trehan** is the Chairman and Managing Director and has been on the Board since incorporation. He is the Promoter and has also been appointed as the 'Chairman - Heart Institute & 'Chief Cardiac Surgeon' for a period of 5 years with effect from August 1, 2021. He holds a bachelor's degree in medicine and surgery from the Faculty of Medicine, University of Lucknow and has been awarded a certificate in specialty of thoracic and cardiac surgery by the American Board of Thoracic Surgery.
- ♦ **Sunil Sachdeva** is a Non-Executive Director of GHL. He was appointed on the Board on August 13, 2004. He holds a Bachelor's Degree in Science (non-medical) from Government College for Girls (previously known as Government College, Gurugram), Maharishi Dayanand University, Rohtak. He has experience in healthcare, infrastructure and finance. He currently serves as the managing director of Ramsons Projects Limited.

- ♦ **Pankaj Prakash Sahni** is the CEO. He has been associated with the company since December 1, 2010. He is a Chartered Accountant and also has a Master's Degree in business administration from the J.L. Kellogg School of Management, Northwestern University. He oversees all hospital operations and guides the overall strategy and growth of the organisation.
- ♦ **Sanjeev Kumar** is the CFO. He has been associated with the company since 2018 and has over two decades of experience in finance and accounting. He is a qualified chartered accountant and a company secretary and holds a bachelor's degree in commerce.

### Industry Overview

With long-term structural factors supporting growth, renewed impetus from Pradhan Mantri Jan Arogya Yojana (PMJAY) and the Government focus shifting onto healthcare sector, the healthcare delivery market is expected to grow at 13-15% CAGR and reach Rs 8.3 trillion in FY2026. From FY2017 to FY2020, major hospital chains have added supply (~70% of their incremental supply during the period) in tier II and III locations, to create a referral network into their main centre by tapping into the underserved creamy tier-II areas. The government is also expected to augment this via the Ayushman Bharat scheme which aims to create 150,000 health and wellness centers (HWCs) (~118,669 HWCs created till May 2022) for strengthening primary and secondary infrastructure in India. Other contributors to the demand are more structural in nature, like, increase in lifestyle-related ailments, increasing medical tourism, rising incomes and changing demography.


#### Overall healthcare delivery market in India



Source: Company RHP

In India, healthcare services are provided by the government as well as private players, and these entities provide both in-patient department (IPD) and out-patient department (OPD) services. However, the provision of healthcare services in India is skewed towards the private players (both for IPD and OPD). This is mainly due to the lack of healthcare spending by the government and high burden on the existing state health infrastructure. The share of treatments (in value terms) by the private players is expected to increase from 62% in FY2017 to nearly 74% in FY2026. The skew is more towards the private players owing to the expansion plans of private players being centered on it, further buttressed by increasing reliance on private facilities till Government infrastructure is properly put in place.

## Share of treatments in value terms



Source: Company RHP

## Key growth drivers of healthcare delivery industry

A combination of economic and demographic factors is expected to drive healthcare demand in India.

- ◆ Government policies to improve healthcare coverage - The Government's long-term goal is to raise its healthcare spending to 2.5% of GDP by 2025 under the National Health policy 2017 from the current 1.3% of GDP.
- ◆ Strengthening of physical health infrastructure: Sub-centres - Upgradation of 0.15 million HWCs (118,669 centres have been made operational as of May 2022) to provide comprehensive healthcare, including coverage of non-communicable diseases and maternal and child health services.
- ◆ Strengthening of physical health infrastructure: Government hospitals - Setting up of 24 new government hospitals and medical colleges and upgradation of existing district hospitals. The intention is to have at least one medical college for three parliamentary constituencies.

## Key strengths of the company

- ◆ **Leading tertiary and quaternary care provider in India, well recognised for clinical expertise in particular in dealing with complicated cases:** Over 2020 to 2022, company's hospital in Gurugram has been rated as the best private hospital in India by Newsweek. GHIL achieved this leadership position with experienced doctors focusing on treating complicated cases and ensuring at the same time the best quality of care. Medanta focuses on quality tertiary and quaternary care, treatment of lifestyle diseases, provision of value-based treatments and work on a high number of critical, complex cases. These procedures have included several complex surgeries, including a paediatric liver transplant for a three-month-old infant in 2020, a 3D printed titanium spine implant procedure in 2017, and a successful intestinal transplant in 2013.
- ◆ **Focus on Clinical Research and Academics:** Medanta is also focused on clinical research and academics. Established in 2009, GHIL's clinical research facility is another driving force behind its high standard of care. The company established 'The Medanta Institutional Tissue Repository' in 2017 to promote biomarker and other tissue-based research. Doctors associated with the company's hospitals have published 451 peer reviewed indexed journal publications between January 2021 and June 2022 and are currently

working with Qure.ai to develop artificial intelligence algorithms with the aim of increasing productivity and improving the accuracy of medical diagnoses. Medanta covers 37 specialties under the Diplomate of National Board (DNB) and Fellowship in National Board programs with over 100 approved seats. Since the inception of GHL's academic program, Medanta has successfully graduated 325 students across 36 specialties for the DNB and, as of June 30, 2022, GHL had 184 students undergoing training at its hospitals

- ◆ **Doctor-led' hospitals driven by skilled and experienced doctors in the healthcare space:** Medanta has adopted a 'doctor-led' model of management. Dr. Trehan leads the entire organisation. The day-to-day operational governance of the hospitals is overseen by a committee comprising the Heads of the major clinical specialties, the Medical Director/CEO/CMD. Each speciality operates on a departmental concept with all doctors in the department working together as a team, thus enabling sub-specialisation, a joint rewards system and a combined team-based approach to patient care. A large amount of autonomy is given to each departmental head to drive their clinical practice. As at June 30, 2022, GHL had a team of more than 6,000 medical professionals, including over 1,300 doctors and over 3,700 nurses and 1,000 paramedical personnel. Medanta's doctors are among the best in their fields and almost all the company's clinical department heads are recognized by their peers in the industry as among the leaders in their specializations. GHL's world-class infrastructure, advanced technology and, most importantly, the doctor-driven culture have allowed the company to attract and retain some of the best clinical leaders in India.
- ◆ **Large-scale hospitals with world-class infrastructure and high-end medical equipment and technology:** GHL's Gurugram hospital has a built-up structure of more than 2 million sq ft with 40 operating rooms and installed bed capacity of 1,391 including 285 ICUs beds as of June 30, 2022. In Lucknow, the company has over 1.3 million sq. ft. designed with installed bed capacity of over 473 as of June 30, 2022, with capacity to accommodate over 900 beds. Patna has approximately 1 million sq. ft. with 228 installed beds as of June 30, 2022 (designed to accommodate over 500 beds). Seamless connectivity is ensured between doctors and patients by combining the in-patient and out-patient areas. A large amount of square-foot-to-bed ratio is maintained across all hospitals and care has been taken to provide patients with a visual connection to the outside environment. GHL places a high focus on infection control practices in design and operations. The company has invested in the latest medical technology and equipment to provide its doctors and medical staff with all the tools they need to practice the highest end of medical care. The company's hospitals are equipped with machines and devices with sophisticated technology.

### Key risks and concerns

- ◆ **GHL is highly dependent on doctors, nurses and other healthcare professionals and the business will be impacted significantly in case the company is unable to attract / retain such professionals:** GHL's performance and growth strategy depends substantially on the ability to attract and retain experienced doctors, nurses and other healthcare professionals in a highly competitive industry. Demand for doctors is highly competitive. The availability of specialist doctors is limited by the training period, which can be up to 15 years and even longer for certain medical specialties. Skilled doctors are in high demand in India, making it difficult to hire and retain senior doctors.
- ◆ **Stringent restrictions to slow down the spread of COVID-19, including limitations on international and local travel, had and could continue to have a negative impact on the business:** The business has been materially and adversely affected due to the ongoing COVID-19 pandemic, and GHL is currently unable to predict its near-term or long-term impact on the business. Effects of a weaker economy on hospitals and restrictions required as a result of COVID-19 have and may continue to result in, among other things, lower patient volumes, deferred surgeries, decline in elective surgeries, higher operational costs and pressure on liquidity. While certain lockdown restrictions have since been relaxed, there is no guarantee that there may not be further lockdowns and curfews. The scope, duration, and frequency of such measures and the adverse effects of COVID-19 remain uncertain and could be severe.

## Consistent financial performance

Revenues grew at CAGR of 20% over FY2020-22 with revenues standing at Rs. 2,166.6 crore in FY2022. This was led by an 8% CAGR in bed capacity while occupancies improved to 60% and ARPOB grew by 4% over the same period. EBIDTA margins consistently improved by 830 bps over the last two years, led by consistent improvement in the margins of mature hospitals (~85% of revenues), which stood at 22.8% in FY2022, while the EBIDTA margins of new hospitals (contributing 15% of revenues) improved to 20%. EBIDTA grew by at CAGR of 55% over FY2020-22 to Rs. 450.5 crore. PAT grew by 5.3x to Rs. 196 crore. RoCE consistently improved to 13.8% in FY2022 from ~5% in FY2020. Same is expected to consistently improve with overall improvement in the profitability in the coming years.

## Valuation and view

GHL is a leading multi-speciality hospital company in the North and Eastern parts of India with consistent financial track record and a strong balance sheet. With bed capacity extended to 3,500 beds and a strong focus on clinical research and expertise, the company is expected to post consistent double-digit revenue growth in the coming years. The company's profitability will consistently improve as operating performance of new hospitals gets better. Further, the company has higher average revenue per occupied bed (ARPOB) and higher margins as compared to some listed companies in the hospital space. GHL is currently trading at FY2022 EV/EBIDTA at 18.7x and 17.7x its lower and upper end of the price band, which is at discount to some of the large players in the space.

### Key operational metrics

Company	Geographic presence	Bed Capacity	ARPOB (Rs. '000/day)	Occupancy Rate (%)
Apollo Hospitals Enterprises	Pan India	9,911	45.3	63.0
Fortis Healthcare	Pan India	3,931	49.3	63.0
Healthcare Global Enterprises	Pan India	1,944	36.7	58.3
Narayana Hrudayalaya	Pan India	6,584	23.7	42.0
Max Healthcare Institute	North India	3,412	59.0	75.0
Global Health	North & East India	2,404	54.6	60.5

Source: Company RHP; Sharekhan Research

### Valuations

Company	Revenues (Rs crore)	EBIDTA margins (%)	Net Profit (Rs crore)	RoCE (%)	EV/EBITDA (x)	Market cap/Sales (x)	D/E (x)
Apollo Hospitals Enterprises	14,676.9	15.0	1108.4	25.5	24.5	4.4	0.5
Fortis Healthcare	5656.7	17.9	790.0	29.7	14.8	3.7	0.4
Healthcare Global Enterprises	1397.8	17.0	-11.9	11.1	11.5	2.9	0.6
Narayana Hrudayalaya	3701.3	17.8	342.1	27.2	22.3	4.3	0.4
Max Healthcare Institute	5218.0	26.7	605.1	32.9	39.3	8.3	0.8
Global Health (upper band)	2,166.6	20.8	196.2	13.8	18.7	4.2	0.7
Global Health (lower band)					17.7	3.7	0.7

Source: Company RHP; Sharekhan Research



**FINANCIALS**
**Profit & Loss account (consolidated)**

	Rs crore				
Particulars	FY2020	FY2021	FY2022	Q1FY22	Q1FY23
<b>Revenue from operations</b>	<b>1,500.4</b>	<b>1,446.7</b>	<b>2,166.6</b>	<b>485.5</b>	<b>617.2</b>
<i>y-o-y growth (%)</i>		-3.6	49.8		27.1
Cost of material	324.8	348.5	542.9	123.9	147.2
<b>Gross Profit</b>	<b>1,175.6</b>	<b>1,098.2</b>	<b>1,623.7</b>	<b>361.6</b>	<b>470.0</b>
<i>Gross margins (%)</i>	78.4	75.9	74.9	74.5	76.2
Employee expenses	538.7	466.3	568.0	132.9	155.5
Other expenses	450.2	434.2	605.2	129.0	182.1
Total Expenditure	1,313.7	1,249.0	1,716.1	385.8	484.8
<b>Operating profit/(loss)</b>	<b>186.7</b>	<b>197.8</b>	<b>450.5</b>	<b>99.7</b>	<b>132.4</b>
<i>OPM (%)</i>	12.4	13.7	20.8	20.5	21.5
Other income	43.8	31.4	39.2	6.1	9.3
Finance cost	51.5	73.4	79.5	16.2	18.5
Depreciation	115.0	123.2	129.7	31.4	36.1
<b>PBT</b>	<b>64.0</b>	<b>32.6</b>	<b>280.5</b>	<b>58.2</b>	<b>87</b>
Tax expense	27.5	3.7	84.4	16.4	28.3
<b>Adjusted PAT/Loss</b>	<b>36.4</b>	<b>28.9</b>	<b>196.2</b>	<b>41.8</b>	<b>58.8</b>
<i>NPM (%)</i>	2.4	2.0	9.1	8.6	9.5

Source: Company RHP; Sharekhan Research

**Balance Sheet (Consolidated)**

	Rs crore				
Particulars	FY2020	FY2021	FY2022	Q1FY22	Q1FY23
<b>Non-current assets</b>					
Property, Plant & Equipment	1,694.6	1,608.4	1,769.6	1,586.0	1,765.3
Capital WIP	381.7	463.8	439.3	477.5	459.1
Goodwill & Other Intangible assets	8.5	7.2	6.3	6.7	5.9
Investments	-	0.1	0.1	0.1	0.1
Other tax assets	-	47.1	59.5	46.5	58.7
Deferred tax assets (net)	-	25.7	27.8	28.5	23.4
Other non-current assets	102.7	39.6	31.3	28.5	58.9
<b>Current assets</b>					
Inventories	38.5	39.8	53.4	64.2	59.4
Trade receivables	149.2	133.6	180.2	156.4	204.2
Cash & cash equivalent	147.6	69.5	119.4	168.5	120.4
Bank balance	102.6	219.8	392.4	238.0	397.8
Other financial assets	-	31.8	51.6	34.8	49.7
Other current assets	40.7	7.7	14.8	19.4	19.2
<b>Total Assets</b>	<b>2,666.0</b>	<b>2,694.0</b>	<b>3,145.4</b>	<b>2,855.0</b>	<b>3,221.9</b>
Equity Capital	49.3	49.6	50.6	49.8	50.6
Other equity	1,300.2	1,332.8	1,565.4	1,375.6	1,624.9
<b>Total Equity</b>	<b>1,349.5</b>	<b>1,382.3</b>	<b>1,616.0</b>	<b>1,425.4</b>	<b>1,675.5</b>
<b>Non-current liabilities</b>					
Borrowing	605.5	577.7	767.6	624.0	712.4
Lease liabilities	270.3	250.7	235.7	246.5	231.4
Other non-current liabilities	-	36.3	55.6	36.5	55.8
Provisions	83.3	42.3	51.1	44.6	54.0
<b>Current liabilities</b>					
Borrowings	-	66.9	70.2	101.0	82.0
Lease liabilities	-	36.1	35.4	36.2	35.6
Trade payables	130.7	131.5	134.3	150.7	180.0
Other liabilities	207.8	142.4	160.2	161.0	177.5
Provisions	18.9	27.7	19.3	29.1	17.6
<b>Total Equity &amp; Liabilities</b>	<b>2,666.0</b>	<b>2,694.1</b>	<b>3,145.4</b>	<b>2,855.0</b>	<b>3,221.8</b>

Source: Company RHP; Sharekhan Research

**Cash flow statement (consolidated)**

Particulars	Rs crore				
	FY2020	FY2021	FY2022	Q1FY22	Q1FY23
Net cash generated from operating activities	175.1	241.8	311.3	76.5	137.6
Net cash generated from investing activities	-87.1	-239.2	-420.8	-48.6	-64.4
Net cash generated from financing activities	-0.9	-80.7	159.6	71.2	-72.3
<b>Net increase/(decrease) in cash and cash equivalent</b>	<b>87.1</b>	<b>-78.1</b>	<b>50.0</b>	<b>99.1</b>	<b>1.0</b>
Cash at the beginning of the year	60.5	147.6	69.5	69.5	119.4
<b>Cash and cash equivalent at end of the year</b>	<b>147.6</b>	<b>69.5</b>	<b>119.5</b>	<b>168.5</b>	<b>120.4</b>

Source: Company RHP; Sharekhan Research

**Key ratios**

Particulars	FY2020	FY2021	FY2022	Q1FY22	Q1FY23
EPS (Rs.)	1.5	1.2	7.7	1.7	2.3
RoCE (%)	5.3	4.9	13.8	12.9	16.0
RoNW (%)	2.7	2.1	12.1	11.7	14.0
OCF/EBIDTA (%)	93.8	122.3	69.1	-	-
Debt/Equity (x)	0.4	0.5	0.5	-	-
Capital turnover ratio	1.1	1.0	1.3	-	-
Asset turnover ratio	0.6	0.6	0.8	-	-

Source: Company RHP; Sharekhan Research

# Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61150000; email id: [compliance@sharekhan.com](mailto:compliance@sharekhan.com);

For any queries or grievances kindly email [igc@sharekhan.com](mailto:igc@sharekhan.com) or contact: [myaccount@sharekhan.com](mailto:myaccount@sharekhan.com)

**Registered Office:** Sharekhan Limited, The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA, Tel: 022 - 67502000/ Fax: 022 - 24327343. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183.

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on [www.sharekhan.com](http://www.sharekhan.com); Investment in securities market are subject to market risks, read all the related documents carefully before investing.